SAN DIEGO - Contineum Therapeutics, Inc. (NASDAQ:CTNM) announced Thursday that its Phase 2 VISTA trial for PIPE-307, an M1 receptor antagonist being developed for relapsing-remitting multiple ...
SAN FRANCISCO and SUZHOU, China, Nov. 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈